Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.47 |
| ▸ | CA2 | P00918 | 6/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.45 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071880 | 0.83 | LMNA (0.57) | THRATHRBLMNACYP1A2CYP2C9 | |
| SCHEMBL4544926 | 0.83 | CES2 (0.52) | CES2CES1CA1CA2CA12 | |
| SCHEMBL8185749 | 0.81 | CES2 (0.50) | CES2CES1SMN1; SMN2LMNAPARP1 | |
| SCHEMBL6653843 | 0.81 | THRB (0.51) | THRATHRBELANESMN1; SMN2LMNA | |
| SCHEMBL27822200 | 0.80 | CA12 (0.52) | THRATHRBCA1CA2CA12 | |
| SCHEMBL10162631 | 0.79 | KMT2A (0.66) | SMN1; SMN2LMNAGAAALDH1A1NPC1 | |
| SCHEMBL3864698 | 0.79 | THRA (0.50) | THRATHRBELANESMN1; SMN2CYP1A2 | |
| SCHEMBL16087039 | 0.79 | THRA (0.50) | THRATHRBCES2CES1CA1 | |
| SCHEMBL31711461 | 0.79 | THRB (0.50) | THRATHRBSMN1; SMN2LMNAPARP10 | |
| SCHEMBL10928698 | 0.79 | ELANE (0.50) | THRATHRBELANELMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106187969-B | A kind of preparation method of 4- aryl-coumarin class compound | 山东省医学科学院药物研究所 | 2019-03-26 | — | — | CN | disclosed |
| CN-106187969-A | A kind of preparation method of 4 aryl-coumarin compounds | 山东省医学科学院药物研究所 | 2016-12-07 | — | — | CN | disclosed |
| CN-104151278-B | The synthetic method of 1-phenyl-2,3-naphthalene dicarboxylic acids acid anhydride and derivative thereof | SHAANXI NORMAL UNIVERSITY (CN) | 2016-04-06 | — | — | CN | disclosed |
| CN-104151278-A | Synthesis method of 1-phenyl-2,3-naphthalene dicarboxylic anhydride and derivatives thereof | UNIV SHAANXI NORMAL | 2014-11-19 | — | — | CN | disclosed |
| US-20120202794-A1 | COMPOUNDS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2012103113-A1 | PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C | GILEAD PHARMASSET, LLC (US) | 2012-08-02 | — | — | WO | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| WO-2005056524-A2 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-06-23 | — | — | WO | disclosed |
| WO-2000024742-A1 | PYRAZOLOPYRIDINE AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202794-A1 | COMPOUNDS | HAVCR2, MAVS, GOT2 | THRA 4493/4885THRB 4060/4885CES2 11/4885 |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | THRA 170/4885THRB 141/4885CES2 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.